Atrophic Gastritic
Conditions
Interventions
Observation group:Oral administration of Weifuchun capsules (produced by Hangzhou Huqingyutang Pharmaceutical Co., Ltd., with the approval number Z20040003, specification: 0.35g per capsule) 4 capsul
Sponsors
Xi'an Aerospace General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18-70 years old; 2. Diagnosed with atrophic gastritis according to the diagnostic criteria of the "Chinese Chronic Gastritis Treatment Guidelines (2022, Shanghai)", with or without intestinal metaplasia and low-grade intraepithelial neoplasia; 3. Hp (Helicobacter pylori) infected patients should first undergo a 14-day Hp eradication treatment.
Exclusion criteria
Exclusion criteria: 1. History of gastric surgery (including endoscopic early cancer, submucosal dissection, and mucosal resection for intraepithelial neoplasia) 2. High-grade intraepithelial neoplasia of the gastric mucosa, gastric cancer, other tumors, severe digestive system diseases, cardiovascular, pulmonary, liver, kidney dysfunction, psychological disorders, pregnant or lactating women; 3. Patients allergic to the ingredients of gastric rejuvenation drugs, currently participating in other clinical trials, having other diseases that may affect this study, or unwilling to undergo follow-up gastroscopy after treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of gastric mucosal atrophy and intestinal metaplasia in histopathology before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| The values of serum pepsinogen (PG I, PG II, PG I/PG II ratio) and gastrin-17 (G-17) before and after treatment.; | — |
Countries
China
Contacts
Public ContactRen Xiaoli
Xi'an Aerospace General Hospital
Outcome results
None listed